In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives

References

• Spinney L. Smallpox and other viruses plagued humans much earlier than suspected. Nature. 2020;584(7819):30–32. doi: 10.1038/d41586-020-02083-0
   PubMedGoogle Scholar
• Minor PD. An introduction to poliovirus: Pathogenesis, vaccination, and the endgame for global eradication. Methods Mol Biol. 2016;1387:1–10.
   PubMedGoogle Scholar
• Rosalik K, Tarney C, Han J. Human Papilloma virus vaccination. Viruses. 2021;13(6):1091. doi: 10.3390/v13061091
   PubMed Web of Science ®Google Scholar
• Pattyn J, Hendrickx G, Vorsters A, et al. Hepatitis B vaccines. J Infect Dis. 2021;224(12 Suppl 2):S343–S351. doi: 10.1093/infdis/jiaa668
   PubMedGoogle Scholar
• Wijesundara DK, Jackson RJ, Ramshaw IA, et al. Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol Cell Biol. 2011;89(3):367–374. doi: 10.1038/icb.2010.118
   PubMed Web of Science ®Google Scholar
• Nicastri E, Kobinger G, Vairo F, et al. Ebola virus disease: Epidemiology, clinical features, management, and prevention. Infect Dis Clin North Am. 2019;33(4):953–976. doi: 10.1016/j.idc.2019.08.005
   PubMed Web of Science ®Google Scholar
• Javanian M, Barary M, Ghebrehewet S, et al. A brief review of influenza virus infection. J Med Virol. 2021;93(8):4638–4646. doi: 10.1002/jmv.26990
   PubMed Web of Science ®Google Scholar
• Sadeghalvad M, Mansourabadi AH, Noori M, et al. Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. Rev Med Virol. 2023;33(1):e2359. doi: 10.1002/rmv.2359
   PubMed Web of Science ®Google Scholar
• Gong Q, Wang C, Chuai X, et al. Monkeypox virus: a re-emergent threat to humans. Virol Sin. 2022;37(4):477–482. doi: 10.1016/j.virs.2022.07.006
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedchem. 2013;8(3):360–376. doi: 10.1002/cmdc.201200487
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi: 10.1038/nrd.2017.243
   PubMed Web of Science ®Google Scholar
• Mao L, Chen Z, Wang Y, et al. Design and application of nanoparticles as vaccine adjuvants against human corona virus infection. J Inorg Biochem. 2021;219:111454. doi: 10.1016/j.jinorgbio.2021.111454
   PubMed Web of Science ®Google Scholar
• Mendes BB, Conniot J, Avital A, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers. 2022;2(1). doi: 10.1038/s43586-022-00104-y
   PubMedGoogle Scholar
• Rappuoli R. Rational design of vaccines. Nat Med. 1997;3(4):374–376. doi: 10.1038/nm0497-374
   PubMed Web of Science ®Google Scholar
• Park WH, Schroder MC. Diphtheria toxin-antitoxin and toxoid: A comparison. Am J Public Health Nations Health. 1932;22(1):7–16. doi: 10.2105/AJPH.22.1.7
   PubMedGoogle Scholar
• Bovier PA. Epaxal®: a virosomal vaccine to prevent hepatitis a infection. Expert Rev Vaccines. 2008;7(8):1141–1150. doi: 10.1586/14760584.7.8.1141
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi: 10.1016/j.smim.2018.05.001
   PubMed Web of Science ®Google Scholar
• Cox JC, Coulter AR. Adjuvants–a classification and review of their modes of action. Vaccine. 1997;15(3):248–256. doi: 10.1016/S0264-410X(96)00183-1
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007;5(7):505–517. doi: 10.1038/nrmicro1681
   PubMed Web of Science ®Google Scholar
• Wang N, Qian R, Liu T, et al. Nanoparticulate carriers Used as vaccine adjuvant delivery systems. Crit Rev Ther Drug Carrier Syst. 2019;36(5):449–484. doi: 10.1615/CritRevTherDrugCarrierSyst.2019027047
   PubMed Web of Science ®Google Scholar
• Garcia A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. APMIS. 2014;122(4):257–267. doi: 10.1111/apm.12143
   PubMed Web of Science ®Google Scholar
• Petkar KC, Patil SM, Chavhan SS, et al. An overview of nanocarrier-based adjuvants for vaccine delivery. Pharmaceutics. 2021;13(4):455. doi: 10.3390/pharmaceutics13040455
   PubMed Web of Science ®Google Scholar
• Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest. 2016;126(3):799–808. doi: 10.1172/JCI81083
   PubMed Web of Science ®Google Scholar
• Anderluzzi G, Schmidt ST, Cunliffe R, et al. Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses. J Control Release. 2021;330:933–944. doi: 10.1016/j.jconrel.2020.10.066
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6(5):723–739. doi: 10.1586/14760584.6.5.723
   PubMed Web of Science ®Google Scholar
• Paston SJ, Brentville VA, Symonds P, et al. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932. doi: 10.3389/fimmu.2021.627932
   PubMed Web of Science ®Google Scholar
• Bian L, Zheng Y, Guo X, et al. Intramuscular inoculation of AS02-adjuvanted Respiratory Syncytial Virus (RSV) F subunit vaccine shows better efficiency and safety than subcutaneous inoculation in BALB/c mice. Front Immunol. 2022;13:938598. doi: 10.3389/fimmu.2022.938598
   PubMed Web of Science ®Google Scholar
• Behzad H, Huckriede ALW, Haynes L, et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis. 2012;205(3):466–473. doi: 10.1093/infdis/jir769
   PubMed Web of Science ®Google Scholar
• Marques RF, de Melo FM, Novais JT, et al. Immune system modulation by the adjuvants poly (I: C) and montanide ISA 720. Front Immunol. 2022;13:910022. doi: 10.3389/fimmu.2022.910022
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Joosten SA, Hoff ST, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32(52):7098–7107. doi: 10.1016/j.vaccine.2014.10.036
   PubMed Web of Science ®Google Scholar
• Clegg CH, Roque R, Perrone LA, et al. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. Plos One. 2014;9(2):e88979. doi: 10.1371/journal.pone.0088979
   PubMed Web of Science ®Google Scholar
• Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines. 2007;6(5):685–698. doi: 10.1586/14760584.6.5.685
   PubMed Web of Science ®Google Scholar
• Li X, Aldayel AM, Cui Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release. 2014;173:148–157. doi:10.1016/j.jconrel.2013.10.032
   PubMed Web of Science ®Google Scholar
• Zhao Q, Sitrin R. Surface phosphophilicity of aluminum-containing adjuvants probed by their efficiency for catalyzing the P–O bond cleavage with chromogenic and fluorogenic substrates. Anal Biochem. 2001;295(1):76–81. doi: 10.1006/abio.2001.5175
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183(10):6186–6197. doi: 10.4049/jimmunol.0901474
   PubMed Web of Science ®Google Scholar
• Fox CB, Orr MT, Van Hoeven N, et al. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J Control Release. 2016;244(Pt A):98–107. doi: 10.1016/j.jconrel.2016.11.011
   PubMedGoogle Scholar
• Garcon N, Di Pasquale A. From discovery to licensure, the adjuvant system story. Hum Vaccin Immunother. 2017;13(1):19–33. doi: 10.1080/21645515.2016.1225635
   PubMed Web of Science ®Google Scholar
• Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682–694. doi: 10.1016/S0140-6736(21)00241-5
   PubMed Web of Science ®Google Scholar
• Kasturi SP, Rasheed MAU, Havenar-Daughton C, et al. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates. Sci Immunol. 2020;5(48). doi: 10.1126/sciimmunol.abb1025
   PubMed Web of Science ®Google Scholar
• Dong H, Wen Z-F, Chen L, et al. Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells. Int J Nanomedicine. 2018;13:3353–3365. doi: 10.2147/IJN.S164097
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Ito A. Tailoring inorganic nanoadjuvants towards next-generation vaccines. Chem Soc Rev. 2018;47(13):4954–4980. doi: 10.1039/C8CS00028J
   PubMed Web of Science ®Google Scholar
• Hem SL, Johnston CT, HogenEsch H. Imject alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine. 2007;25(27):4985–4986. doi: 10.1016/j.vaccine.2007.04.078
   PubMed Web of Science ®Google Scholar
• Li A, Qin L, Zhu D, et al. Signalling pathways involved in the activation of dendritic cells by layered double hydroxide nanoparticles. Biomaterials. 2010;31(4):748–756. doi: 10.1016/j.biomaterials.2009.09.095
   PubMed Web of Science ®Google Scholar
• Wu Y, Huang X, Yuan L, et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamster. Sci Transl Med. 2021;13(606):eabg1143. doi: 10.1126/scitranslmed.abg1143
   Web of Science ®Google Scholar
• Wang C, Guan Y, Lv M, et al. Manganese increases the sensitivity of the Cgas-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity. 2018;48(4):675–687 e7. doi: 10.1016/j.immuni.2018.03.017
   PubMed Web of Science ®Google Scholar
• Fan N, Chen K, Zhu R, et al. Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. Sci Adv. 2022;8(51):eabq3500. doi: 10.1126/sciadv.abq3500
   PubMed Web of Science ®Google Scholar
• Mulens-Arias V, Rojas JM, Barber DF. The use of iron oxide nanoparticles to reprogram macrophage responses and the immunological tumor microenvironment. Front Immunol. 2021;12:693709. doi: 10.3389/fimmu.2021.693709
   PubMed Web of Science ®Google Scholar
• Li F, Nie W, Zhang F, et al. Engineering magnetosomes for high-performance cancer vaccination. ACS Cent Sci. 2019;5(5):796–807. doi: 10.1021/acscentsci.9b00060
   PubMed Web of Science ®Google Scholar
• Guo Y, Tang L. A magnetic nanovaccine enhances cancer immunotherapy. ACS Cent Sci. 2019;5(5):747–749. doi: 10.1021/acscentsci.9b00325
   PubMed Web of Science ®Google Scholar
• Mahony D, Cavallaro AS, Stahr F, et al. Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. Small. 2013;9(18):3138–3146. doi: 10.1002/smll.201300012
   PubMed Web of Science ®Google Scholar
• Tayeb HH, Sainsbury F. Nanoemulsions in drug delivery: formulation to medical application. Nanomedicine (Lond). 2018;13(19):2507–2525. doi: 10.2217/nnm-2018-0088
   PubMed Web of Science ®Google Scholar
• Dube JY, McIntosh F, Zarruk JG, et al. Synthetic mycobacterial molecular patterns partially complete Freund’s adjuvant. Sci Rep. 2020;10(1):5874. doi: 10.1038/s41598-020-62543-5
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, Nest GV, et al. The history of MF59 ® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13–30. doi: 10.1586/erv.12.140
   PubMed Web of Science ®Google Scholar
• Klucker MF, Dalençon F, Probeck P, et al. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J Pharm Sci. 2012;101(12):4490–4500. doi: 10.1002/jps.23311
   PubMed Web of Science ®Google Scholar
• Mendes A, Azevedo-Silva J, Fernandes JC. From sharks to yeasts: squalene in the development of vaccine adjuvants. Pharmaceuticals (Basel). 2022;15(3):265. doi: 10.3390/ph15030265
   PubMedGoogle Scholar
• Ravera F, Dziza K, Santini E, et al. Emulsification and emulsion stability: The role of the interfacial properties. Adv Colloid Interface Sci. 2021;288:102344. doi: 10.1016/j.cis.2020.102344
   PubMed Web of Science ®Google Scholar
• Garcon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012;11(3):349–366. doi: 10.1586/erv.11.192
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 2002;1(1):111–118. doi: 10.1586/14760584.1.1.111
   PubMedGoogle Scholar
• van Doorn E, Liu H, Huckriede A, et al. Safety and tolerability evaluation of the use of montanide ISA™51 as vaccine adjuvant: A systematic review. Hum Vaccin Immunother. 2016;12(1):159–169. doi: 10.1080/21645515.2015.1071455
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, De Gregorio E, et al. The mechanism of action of MF59 – an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341–4348. doi: 10.1016/j.vaccine.2011.09.061
   PubMed Web of Science ®Google Scholar
• Brito LA, Chan M, Shaw CA, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22(12):2118–2129. doi: 10.1038/mt.2014.133
   PubMed Web of Science ®Google Scholar
• Chen Z, Hao X, Wang H, et al. Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses. J Control Release. 2022;349:699–711. doi: 10.1016/j.jconrel.2022.07.032
   PubMed Web of Science ®Google Scholar
• Budai M, Szogyi M. Liposomes as drug carrier systems. Preparation, classification and therapeutic advantages of liposomes. Acta Pharm Hung. 2001;71(1):114–118.
   PubMedGoogle Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi: 10.1186/1556-276X-8-102
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today. 1990;11(3):89–97. doi: 10.1016/0167-5699(90)90034-7
   PubMedGoogle Scholar
• Wang N, Chen M, Wang T. Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. J Control Release. 2019;303:130–150. doi: 10.1016/j.jconrel.2019.04.025
   PubMed Web of Science ®Google Scholar
• Syed YY. Recombinant Zoster vaccine (Shingrix((r))): A review in Herpes Zoster. Drugs Aging. 2018;35(12):1031–1040. doi: 10.1007/s40266-018-0603-x
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55–63. doi: 10.1080/14760584.2016.1213632
   PubMed Web of Science ®Google Scholar
• Alving CR, Rao M, Steers NJ, et al. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines. 2012;11(6):733–744. doi: 10.1586/erv.12.35
   PubMed Web of Science ®Google Scholar
• Morein B, Lövgren K, Höglund S, et al. The ISCOM: an immunostimulating complex. Immunol Today. 1987;8(11):333–338. doi: 10.1016/0167-5699(87)90008-9
   PubMedGoogle Scholar
• Baz Morelli A, Becher D, Koernig S, et al. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol. 2012;61(7):935–943. doi: 10.1099/jmm.0.040857-0
   PubMed Web of Science ®Google Scholar
• Magnusson SE, Altenburg AF, Bengtsson KL, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224–233. doi: 10.1007/s12026-018-8991-x
   PubMed Web of Science ®Google Scholar
• Alving CR, Matyas GR, Torres O, et al. Adjuvants for vaccines to drugs of abuse and addiction. Vaccine. 2014;32(42):5382–5389. doi: 10.1016/j.vaccine.2014.07.085
   PubMed Web of Science ®Google Scholar
• Tenchov R, Bird R, Curtze AE, et al. Lipid nanoparticles─From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015. doi: 10.1021/acsnano.1c04996
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–838. doi: 10.1038/s41573-021-00283-5
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Satapathy SR, Dutta T. Delivery Strategies for mRNA Vaccines. Pharmaceut Med. 2022;36(1):11–20. doi: 10.1007/s40290-021-00417-5
   PubMed Web of Science ®Google Scholar
• Li Y, Tenchov R, Smoot J, et al. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci. 2021;7(4):512–533. doi: 10.1021/acscentsci.1c00120
   PubMed Web of Science ®Google Scholar
• DeFrancesco L. Whither COVID-19 vaccines? Nat Biotechnol. 2020;38(10):1132–1145. doi: 10.1038/s41587-020-0697-7
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato T, Endo R, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer. 2021;9(7):e002852. doi: 10.1136/jitc-2021-002852
   PubMed Web of Science ®Google Scholar
• Li M, Li Y, Li S, et al. The nano delivery systems and applications of mRNA. Eur J Med Chem. 2022;227:113910. doi: 10.1016/j.ejmech.2021.113910
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–974. doi: 10.1016/j.jconrel.2013.09.015
   PubMed Web of Science ®Google Scholar
• Carroll EC, Jin L, Mori A, et al. The vaccine adjuvant Chitosan promotes cellular immunity via DNA sensor Cgas-STING-Dependent induction of type I interferons. Immunity. 2016;44(3):597–608. doi: 10.1016/j.immuni.2016.02.004
   PubMed Web of Science ®Google Scholar
• Albert C, Beladjine M, Tsapis N, et al. Pickering emulsions: Preparation processes, key parameters governing their properties and potential for pharmaceutical applications. J Control Release. 2019;309:302–332. doi: 10.1016/j.jconrel.2019.07.003
   PubMed Web of Science ®Google Scholar
• Xia Y, Wu J, Wei W, et al. Exploiting the pliability and lateral mobility of pickering emulsion for enhanced vaccination. Nat Mater. 2018;17(2):187–194. doi: 10.1038/nmat5057
   PubMed Web of Science ®Google Scholar
• Zhu M, Shi Y, Shan Y, et al. Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics. J Nanobiotechnology. 2021;19(1):387. doi: 10.1186/s12951-021-01131-9
   PubMed Web of Science ®Google Scholar
• Peng S, Cao F, Xia Y, et al. Particulate alum via pickering emulsion for an enhanced COVID-19 vaccine adjuvant. Adv Mater. 2020;32(40):e2004210. doi: 10.1002/adma.202004210
   PubMed Web of Science ®Google Scholar
• Curley SM, Putnam D. Biological nanoparticles in vaccine development. Front Bioeng Biotechnol. 2022;10:867119. doi: 10.3389/fbioe.2022.867119
   PubMed Web of Science ®Google Scholar
• Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol. 2002;21(12):895–913. doi: 10.1089/104454902762053855
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578–582. doi: 10.1038/s41586-020-2608-y
   PubMed Web of Science ®Google Scholar
• Qian C, Liu X, Xu Q, et al. Recent progress on the versatility of virus-like particles. Vaccines (Basel). 2020;8(1):139. doi: 10.3390/vaccines8010139
   PubMed Web of Science ®Google Scholar
• Yilmaz IC, Ipekoglu EM, Bulbul A, et al. Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. Allergy. 2022;77(1):258–270. doi: 10.1111/all.15091
   PubMed Web of Science ®Google Scholar
• Hills RA, Howarth M. Virus-like particles against infectious disease and cancer: guidance for the nano-architect. Curr Opin Biotechnol. 2022;73:346–354. doi: 10.1016/j.copbio.2021.09.012
   PubMed Web of Science ®Google Scholar
• Li M, Liang Z, Chen C, et al. Virus-like particle-templated silica-adjuvanted nanovaccines with enhanced humoral and cellular immunity. ACS Nano. 2022;16(7):10482–10495. doi: 10.1021/acsnano.2c01283
   PubMedGoogle Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20(Suppl_5):B17–23. doi: 10.1016/S0264-410X(02)00512-1
   PubMedGoogle Scholar
• Cui B, Liu X, Fang Y, et al. Flagellin as a vaccine adjuvant. Expert Rev Vaccines. 2018;17(4):335–349. doi: 10.1080/14760584.2018.1457443
   PubMed Web of Science ®Google Scholar
• Vasou A, Sultanoglu N, Goodbourn S, et al. Targeting pattern recognition receptors (prr) for vaccine adjuvantation: From synthetic PRR agonists to the potential of defective interfering particles of viruses. Viruses. 2017;9(7):186. doi: 10.3390/v9070186
   PubMed Web of Science ®Google Scholar
• Sartorio MG, Pardue EJ, Feldman MF, et al. Bacterial outer membrane vesicles: From discovery to applications. Annu Rev Microbiol. 2021;75(1):609–630. doi: 10.1146/annurev-micro-052821-031444
   PubMedGoogle Scholar
• Qing S, Lyu C, Zhu L, et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020;32(47):e2002085. doi: 10.1002/adma.202002085
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–289. doi: 10.1146/annurev-cellbio-101512-122326
   PubMed Web of Science ®Google Scholar
• Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820(7):940–948. doi: 10.1016/j.bbagen.2012.03.017
   PubMed Web of Science ®Google Scholar
• Wang Z, Popowski KD, Zhu D, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat Biomed Eng. 2022;6(7):791–805. doi: 10.1038/s41551-022-00902-5
   PubMed Web of Science ®Google Scholar
• Friedman-Klabanoff DJ, Berry AA, Travassos MA, et al. Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Vaccine. 2021;39(8):1195–1200. doi: 10.1016/j.vaccine.2020.12.023
   PubMed Web of Science ®Google Scholar
• Liang H, Poncet D, Seydoux E, et al. The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine. NPJ Vaccines. 2019;4(1):19. doi: 10.1038/s41541-019-0116-6
   PubMedGoogle Scholar
• Olafsdottir TA, Lingnau K, Nagy E, et al. IC31 ® , a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol. 2009;69(3):194–202. doi: 10.1111/j.1365-3083.2008.02225.x
   PubMed Web of Science ®Google Scholar
• Li L, Honda-Okubo Y, Baldwin J, et al. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine. 2022;40(23):3182–3192. doi: 10.1016/j.vaccine.2022.04.041
   PubMed Web of Science ®Google Scholar
• Sultan H, Salazar AM, Celis E. Poly-ICLC, a multi-functional immune modulator for treating cancer. Semin Immunol. 2020;49:101414. doi: 10.1016/j.smim.2020.101414
   PubMed Web of Science ®Google Scholar
• Gai WW, Zhang Y, Zhou D-H, et al. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. Virol Sin. 2011;26(2):81–94. doi: 10.1007/s12250-011-3183-z
   PubMedGoogle Scholar
• Portielje JE, Gratama J, van Ojik HH, et al. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother. 2003;52(3):133–144. doi: 10.1007/s00262-002-0356-5
   PubMed Web of Science ®Google Scholar
• Yoon HA, Aleyas AG, George JA, et al. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses. Microbiol Immunol. 2006;50(2):83–92. doi: 10.1111/j.1348-0421.2006.tb03773.x
   PubMed Web of Science ®Google Scholar
• Wang L, He Y, He T, et al. Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers. Biomaterials. 2020;255:120208. doi: 10.1016/j.biomaterials.2020.120208
   PubMed Web of Science ®Google Scholar
• Pulendran B, P SA, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–475. doi: 10.1038/s41573-021-00163-y
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Omer SB. Why and how vaccines work. Cell. 2020;183(2):290–295. doi: 10.1016/j.cell.2020.09.040
   PubMed Web of Science ®Google Scholar
• Nanishi E, Borriello F, O’Meara TR, et al. An aluminum hydroxide: CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022;14(629):eabj5305. doi: 10.1126/scitranslmed.abj5305
   PubMed Web of Science ®Google Scholar
• Bajoria S, Kaur K, Kumru OS, et al. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Hum Vaccin Immunother. 2022;18(5):2079346. doi: 10.1080/21645515.2022.2079346
   PubMed Web of Science ®Google Scholar
• Chen W, Jiang M, Yu W, et al. CpG-Based nanovaccines for cancer immunotherapy. Int J Nanomedicine. 2021;16:5281–5299. doi: 10.2147/IJN.S317626
   PubMed Web of Science ®Google Scholar
• Das A, Ali N. Nanovaccine: an emerging strategy. Expert Rev Vaccines. 2021;20(10):1273–1290. doi: 10.1080/14760584.2021.1984890
   PubMed Web of Science ®Google Scholar
• Smith DM, Simon JK, Baker JR. Applications of nanotechnology for immunology. Nat Rev Immunol. 2013;13(8):592–605. doi: 10.1038/nri3488
   PubMed Web of Science ®Google Scholar
• Di J, Du Z, Wu K, et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm Res. 2022;39(1):105–114. doi: 10.1007/s11095-022-03166-5
   PubMed Web of Science ®Google Scholar
• Keikha R, Daliri K, Jebali A. The use of nanobiotechnology in immunology and vaccination. Vaccines (Basel). 2021;9(2):74. doi: 10.3390/vaccines9020074
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–1608. doi: 10.1038/nm.3409
   PubMed Web of Science ®Google Scholar
• Sun B, Wang X, Ji Z, et al. NLRP3 inflammasome activation induced by engineered nanomaterials. Small. 2013;9(9–10):1595–1607. doi: 10.1002/smll.201201962
   PubMed Web of Science ®Google Scholar
• Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol. 2001;21(1–3):75–85. doi: 10.1615/CritRevImmunol.v21.i1-3.50
   PubMed Web of Science ®Google Scholar
• Storni T, KUNDIG T, SENTI G, et al. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57(3):333–355. doi: 10.1016/j.addr.2004.09.008
   PubMed Web of Science ®Google Scholar
• Andrade S, Ramalho MJ, Loureiro JA, et al. Liposomes as biomembrane models: Biophysical techniques for drug-membrane interaction studies. J Mol Liq. 2021;334:116141. doi: 10.1016/j.molliq.2021.116141
   Web of Science ®Google Scholar
• Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180(6):1044–1066. doi: 10.1016/j.cell.2020.02.041
   PubMed Web of Science ®Google Scholar
• Coccia M, Collignon C, Hervé C, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017;2(1):25. doi: 10.1038/s41541-017-0027-3
   PubMed Web of Science ®Google Scholar
• Pifferi C, Fuentes R, Fernandez-Tejada A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 2021;5(3):197–216. doi: 10.1038/s41570-020-00244-3
   PubMed Web of Science ®Google Scholar
• Shi S, Zhu H, Xia X, et al. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167–3178. doi: 10.1016/j.vaccine.2019.04.055
   PubMed Web of Science ®Google Scholar
• Wu D, Meydani SN. Age-associated changes in immune function: impact of vitamin E intervention and the underlying mechanisms. Endocr Metab Immune Disord Drug Targets. 2014;14(4):283–289. doi: 10.2174/1871530314666140922143950
   PubMed Web of Science ®Google Scholar
• Jie J, Liu G, Feng J, et al. MF59 promoted the combination of CpG ODN1826 and MUC1-MBP vaccine-induced antitumor activity involved in the enhancement of DC maturation by prolonging the local retention time of antigen and down-regulating of IL-6/STAT3. Int J Mol Sci. 2022;23(18):10887. doi: 10.3390/ijms231810887
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24(3):179–191. doi: 10.3109/1061186X.2015.1051049
   PubMed Web of Science ®Google Scholar
• Aoshi T, Koyama S, Kobiyama K, et al. Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol. 2011;1(4):226–232. doi: 10.1016/j.coviro.2011.07.002
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. doi: 10.1038/s41590-021-01122-w
   PubMed Web of Science ®Google Scholar